Post-Marketing Surveillance to Evaluate the Safety and Effectiveness of Zastaprazan Citrate
Key facts
- Who runs it
- Jeil Pharmaceutical Co., Ltd.
- Where
- South Korea1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 3,000 people, planned
- Started
- 2 Nov 2024
- Expected to end
- 31 Dec 2029
- Type of study
- Observational
- Treatments tested
- zastaprazan citrate
- Record updated
- 26 October 2026
Who can take part
- Age
- 19 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (6)Hide the full registry criteria
Who can take part
- Patients who receive their first prescription for zastaprazan citrate in accordance with the approved prescribing information after execution of the study agreement
- Patients who have received an explanation of the study and voluntarily signed the informed consent form
Who cannot take part
- atients currently receiving products containing atazanavir, nelfinavir, or rilpivirine
- Patients with hypersensitivity or a history of hypersensitivity to zastaprazan citrate or any component of the product
- Patients with hereditary disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption. This exclusion criterion does not apply to the orally disintegrating tablet formulation
- Patients who are pregnant or breastfeeding
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Erosive gastroesophageal reflux disease
This trial is currently available in South Korea.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This post-marketing surveillance aims to evaluate the safety and effectiveness of zastaprazan citrate administered in Korean patients receiving the drug in accordance with the approved prescribing information.
The group in the trial
- Erosive Gastroesophageal Reflux Disease
Patients administrated zastaprazan citrate
Treatment: zastaprazan citrate
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Criteria questions
- Built from NCT07894939, who can take part
- Record updated
- 26 October 2026